These results and clinical efficacy data from expansion cohorts, including patients with chronic lymphocytic leukemia (CLL) and AML[124], proved that five of six patients with mutant TP53 had some clinical effect. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.